UBS analyst Danielle Antalffy initiated coverage of Enovis with a Buy rating and $75 price target. The analyst believes the company can deliver orthopedics market-leading high single digit sales growth through at least 2027 as the portfolio mix shifts to higher growth reconstructive. The firm sees several potential upside drivers to Enovis’ growth, including the acquisition of LimaCorporate and international cross selling opportunities. For the latest breaking news, listen to Fly Radio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENOV:
